ONSEMI IS TO BUY SYNAPTICS FOR $123 PER SHARE IN CASH UNDER A REVISED MERGER AGREEMENT, VALUING THE DEAL AT $5.70 BLN, SOURCES SAY, WITH THE TRANSACTION EXPECTED TO BE IMMEDIATELY ACCRETIVE TO ONSEMI'S NON-GAAP EPS AND FINANCED WITH CASH AND COMMITTED DEBT FUNDING FROM MORGAN STANLEY.